GE HealthCare has signed a distribution and services agreement with CardioNavix, part of the CDL Nuclear Technologies group, to broaden access to its cardiac PET imaging agent, Flyrcado (flurpiridaz F18), across the United States.

CardioNavix, which operates under the Pennsylvania-based CDL Nuclear Technologies umbrella, provides cardiac PET imaging services to nearly 225 U.S. sites and supports more than 220,000 procedures annually. The collaboration is expected to help bring Flyrcado into wider use in outpatient settings, including private cardiology practices and hospitals.

The agreement combines GE HealthCare’s manufacturing capabilities and distribution infrastructure with CardioNavix’s experience in clinical workflow, operations support, and site enablement. Initial distribution of Flyrcado is scheduled to begin later this year, with broader rollout planned for 2026.
Flyrcado, a PET myocardial perfusion imaging (MPI) agent, was approved earlier in 2025 for the evaluation of coronary artery disease. It has been shown to offer higher diagnostic accuracy than SPECT MPI in clinical studies, including the Phase III AURORA trial.

"This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care," said Eric Ruedinger, vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada.

Lon Wilson, CEO of CDL Nuclear Technologies, added, "We’re proud that CardioNavix will be the first distributor to bring Flyrcado to private practice cardiology."

Roughly six million MPI procedures are performed in the U.S. each year. While PET accounts for only a small portion of those, usage has been growing among cardiology providers, particularly in office-based settings.

The agreement aligns with GE HealthCare’s strategy to expand access to advanced imaging agents through partnerships that strengthen infrastructure in outpatient care.

Molecular Imaging Homepage